Page 1 of 94
WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
WITH VERIFIED ANSWERS DETAILED RATIONALES
GRADED A+
WGU D116 Advanced Pharmacology Final Exam
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1–45)
1. A nurse practitioner is reviewing pharmacokinetic principles with a student and is asked to
identify which phase of pharmacokinetics is primarily affected when a patient has significant
liver impairment. Which phase should the nurse practitioner identify?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: C. Metabolism, or biotransformation, occurs primarily in the liver via enzymes such
as the cytochrome P450 system. Hepatic impairment significantly alters drug metabolism,
leading to drug accumulation and toxicity risk.
2. A nurse practitioner is evaluating a drug's safety profile and notes that it has a high
therapeutic index. Which of the following conclusions is most appropriate regarding this
medication's safety?
A. Extremely potent requiring minimal dosing
B. Highly toxic with dangerous adverse effects
C. Relatively safe with a wide margin
D. Slowly absorbed requiring extended intervals
1|Page
,Page 2 of 94
Rationale: C. The therapeutic index is the ratio of the toxic dose to the therapeutic dose
(LD50/ED50). A high therapeutic index indicates a wide margin of safety, meaning the drug is
relatively safe.
3. A nurse practitioner is initiating a medication with a half-life of 6 hours and needs to
determine when the drug will reach steady-state concentration. Approximately how many
hours should the nurse practitioner anticipate?
A. 12 hours
B. 18 hours
C. 24 to 30 hours
D. 48 hours
Rationale: C. Steady state is reached after approximately 4-5 half-lives. For a drug with a 6-
hour half-life, steady state would be reached in approximately 24-30 hours.
4. A nurse practitioner is reviewing the metabolic pathways of a newly prescribed medication
and notes that it undergoes glucuronidation. Which type of metabolic reaction is this
considered?
A. Phase I oxidation reaction
B. Phase II conjugation reaction
C. Phase I hydrolysis reaction
D. Phase I reduction reaction
Rationale: B. Phase II reactions involve conjugation, such as glucuronidation, which makes the
drug more polar and water-soluble for excretion. Oxidation, hydrolysis, and reduction are
Phase I reactions.
5. A nurse practitioner is explaining the mechanism of action of a newly prescribed
medication and describes it as an agonist. Which of the following best describes this drug's
action?
A. Binds to a receptor and activates it
B. Blocks a receptor site preventing activation
C. Prevents other drugs from binding to receptors
2|Page
,Page 3 of 94
D. Degrades neurotransmitters in the synapse
Rationale: A. Agonists mimic the action of endogenous ligands by binding to and activating
receptors to produce a biological response.
6. A nurse practitioner is considering the route of administration for a medication and wants
to avoid the first-pass effect. Which of the following should the nurse practitioner recognize
as the definition of this phenomenon?
A. Binding of drugs to plasma proteins
B. Excretion of drugs through the kidneys
C. Metabolism of a drug in the liver before reaching systemic circulation
D. The time it takes for a drug to reach the brain
Rationale: C. Oral drugs are absorbed in the GI tract and carried to the liver via the portal
vein, where they may be significantly metabolized before entering the bloodstream.
7. A nurse practitioner is reviewing a patient's laboratory results and notes a low albumin
level. Which pharmacokinetic parameter is most likely to be affected in this patient?
A. Increased volume of distribution for protein-bound drugs
B. Increased free fraction of highly protein-bound drugs
C. Decreased absorption of oral medications
D. Decreased renal excretion of all drugs
Rationale: B. Albumin is the most important protein for drug binding in plasma. When
albumin is low, more free (unbound) drug is available, increasing the risk of toxicity.
8. A nurse practitioner is explaining the difference between pharmacokinetics and
pharmacodynamics to a patient. Which of the following statements best describes these
concepts?
A. Pharmacokinetics is drug-receptor interactions; pharmacodynamics is drug movement
B. Pharmacokinetics is drug movement; pharmacodynamics is drug-receptor interactions
C. Pharmacokinetics and pharmacodynamics are the same concept
D. Pharmacokinetics studies toxicity; pharmacodynamics studies efficacy
Rationale: B. Pharmacokinetics is the study of drug movement through the body (ADME),
3|Page
, Page 4 of 94
while pharmacodynamics is the study of drug-receptor interactions and their effects on
biological systems.
9. A nurse practitioner is preparing to administer a medication intravenously and is asked
about the bioavailability of this route. What is the bioavailability of an intravenously
administered drug?
A. 50%
B. 75%
C. 90%
D. 100%
Rationale: D. Intravenous administration provides 100% bioavailability because the drug is
directly delivered into the bloodstream, bypassing absorption barriers.
10. A nurse practitioner is evaluating a patient who is taking a highly protein-bound
medication. What effect does high protein binding have on the duration of the drug's action?
A. Shorter duration of action
B. Longer duration of action
C. More rapid elimination
D. Higher volume of distribution
Rationale: B. Highly protein-bound drugs have a longer duration of action because only the
free (unbound) fraction is pharmacologically active and subject to elimination. Bound drug is
inactive and remains in circulation.
11. A nurse practitioner is calculating the volume of distribution for a medication and is asked
to explain this parameter to a student. Which definition is most accurate?
A. The actual volume of body fluids
B. The theoretical volume needed to contain total drug amount at the same concentration as in
plasma
C. The volume of blood in the body
D. The volume of the liver
4|Page
WGU D116 ADVANCED PHARMACOLOGY FINAL EXAM
WITH VERIFIED ANSWERS DETAILED RATIONALES
GRADED A+
WGU D116 Advanced Pharmacology Final Exam
Section 1: Pharmacokinetics & Pharmacodynamics (Questions 1–45)
1. A nurse practitioner is reviewing pharmacokinetic principles with a student and is asked to
identify which phase of pharmacokinetics is primarily affected when a patient has significant
liver impairment. Which phase should the nurse practitioner identify?
A. Absorption
B. Distribution
C. Metabolism
D. Excretion
Rationale: C. Metabolism, or biotransformation, occurs primarily in the liver via enzymes such
as the cytochrome P450 system. Hepatic impairment significantly alters drug metabolism,
leading to drug accumulation and toxicity risk.
2. A nurse practitioner is evaluating a drug's safety profile and notes that it has a high
therapeutic index. Which of the following conclusions is most appropriate regarding this
medication's safety?
A. Extremely potent requiring minimal dosing
B. Highly toxic with dangerous adverse effects
C. Relatively safe with a wide margin
D. Slowly absorbed requiring extended intervals
1|Page
,Page 2 of 94
Rationale: C. The therapeutic index is the ratio of the toxic dose to the therapeutic dose
(LD50/ED50). A high therapeutic index indicates a wide margin of safety, meaning the drug is
relatively safe.
3. A nurse practitioner is initiating a medication with a half-life of 6 hours and needs to
determine when the drug will reach steady-state concentration. Approximately how many
hours should the nurse practitioner anticipate?
A. 12 hours
B. 18 hours
C. 24 to 30 hours
D. 48 hours
Rationale: C. Steady state is reached after approximately 4-5 half-lives. For a drug with a 6-
hour half-life, steady state would be reached in approximately 24-30 hours.
4. A nurse practitioner is reviewing the metabolic pathways of a newly prescribed medication
and notes that it undergoes glucuronidation. Which type of metabolic reaction is this
considered?
A. Phase I oxidation reaction
B. Phase II conjugation reaction
C. Phase I hydrolysis reaction
D. Phase I reduction reaction
Rationale: B. Phase II reactions involve conjugation, such as glucuronidation, which makes the
drug more polar and water-soluble for excretion. Oxidation, hydrolysis, and reduction are
Phase I reactions.
5. A nurse practitioner is explaining the mechanism of action of a newly prescribed
medication and describes it as an agonist. Which of the following best describes this drug's
action?
A. Binds to a receptor and activates it
B. Blocks a receptor site preventing activation
C. Prevents other drugs from binding to receptors
2|Page
,Page 3 of 94
D. Degrades neurotransmitters in the synapse
Rationale: A. Agonists mimic the action of endogenous ligands by binding to and activating
receptors to produce a biological response.
6. A nurse practitioner is considering the route of administration for a medication and wants
to avoid the first-pass effect. Which of the following should the nurse practitioner recognize
as the definition of this phenomenon?
A. Binding of drugs to plasma proteins
B. Excretion of drugs through the kidneys
C. Metabolism of a drug in the liver before reaching systemic circulation
D. The time it takes for a drug to reach the brain
Rationale: C. Oral drugs are absorbed in the GI tract and carried to the liver via the portal
vein, where they may be significantly metabolized before entering the bloodstream.
7. A nurse practitioner is reviewing a patient's laboratory results and notes a low albumin
level. Which pharmacokinetic parameter is most likely to be affected in this patient?
A. Increased volume of distribution for protein-bound drugs
B. Increased free fraction of highly protein-bound drugs
C. Decreased absorption of oral medications
D. Decreased renal excretion of all drugs
Rationale: B. Albumin is the most important protein for drug binding in plasma. When
albumin is low, more free (unbound) drug is available, increasing the risk of toxicity.
8. A nurse practitioner is explaining the difference between pharmacokinetics and
pharmacodynamics to a patient. Which of the following statements best describes these
concepts?
A. Pharmacokinetics is drug-receptor interactions; pharmacodynamics is drug movement
B. Pharmacokinetics is drug movement; pharmacodynamics is drug-receptor interactions
C. Pharmacokinetics and pharmacodynamics are the same concept
D. Pharmacokinetics studies toxicity; pharmacodynamics studies efficacy
Rationale: B. Pharmacokinetics is the study of drug movement through the body (ADME),
3|Page
, Page 4 of 94
while pharmacodynamics is the study of drug-receptor interactions and their effects on
biological systems.
9. A nurse practitioner is preparing to administer a medication intravenously and is asked
about the bioavailability of this route. What is the bioavailability of an intravenously
administered drug?
A. 50%
B. 75%
C. 90%
D. 100%
Rationale: D. Intravenous administration provides 100% bioavailability because the drug is
directly delivered into the bloodstream, bypassing absorption barriers.
10. A nurse practitioner is evaluating a patient who is taking a highly protein-bound
medication. What effect does high protein binding have on the duration of the drug's action?
A. Shorter duration of action
B. Longer duration of action
C. More rapid elimination
D. Higher volume of distribution
Rationale: B. Highly protein-bound drugs have a longer duration of action because only the
free (unbound) fraction is pharmacologically active and subject to elimination. Bound drug is
inactive and remains in circulation.
11. A nurse practitioner is calculating the volume of distribution for a medication and is asked
to explain this parameter to a student. Which definition is most accurate?
A. The actual volume of body fluids
B. The theoretical volume needed to contain total drug amount at the same concentration as in
plasma
C. The volume of blood in the body
D. The volume of the liver
4|Page
